NEW YORK (GenomeWeb News) – The National Cancer Institute wants to push forward protein-focused cancer research technologies by investing between $75 million and $120 million in centers that will conduct biomarker discovery, verification, and new cancer proteomics studies.
The Proteome Characterization Centers (PCC) grants program is the second phase in NCI’s Clinical Proteomic Technologies for Cancer (CPTC) initiative, which was started four years ago to develop technologies for identifying and quantifying proteins that could be useful as cancer biomarkers.
Phase one of the CPTC program established five multidisciplinary centers that showed they could be effective in addressing analytical variability problems in proteomics. Now, the second phase will build a network of centers that will target biomarkers and will aim to improve tools for protein detection, identification, and quantification.
The PCCs will use discovery units and verification units to implement the two-step process in the biomarker development pipeline, and the findings from these studies will be made public through a central data center.
“[We] want to develop a much greater understanding of cancer at the molecular level,” Chris Kinsinger of NCI’s Office of Cancer Clinical Proteomics Research told GenomeWeb Daily News this week.